StockDuty ← Dashboard Oct 30, 2026 12:50 PM ET
SignalEU/UK

AstraZeneca profit +23% to $3.12B, oncology now 48% of revenue and up 17% on Tagrisso and Imfinzi. The $1.5B annual savings plan carries up to $2B in restructuring charges and gets reinvested into 180

AstraZeneca profit jumped 23% on cancer drugs alongside a savings plan.

What happened: AstraZeneca reported a 23% rise in third-quarter net profit on cancer drug sales and unveiled a savings programme called Reshaping for Sustainable Growth. Key numbers: Profit after tax $3.12 billion, up 23%. Revenue $16.2 billion, up 7%. Oncology sales $7.8 billion, up 17%, 48% of total. Why it matters: The company plans to reinvest the savings mainly in its pipeline of more than 180 projects, and it confirmed its 2026 outlook and its $80 billion revenue target for 2030. Restructuring could mean job cuts, though none have been announced.
AstraZeneca reported a 23% rise in third-quarter net profit on cancer drug sales and unveiled a savings programme called Reshaping for Sustainable Growth.
The company plans to reinvest the savings mainly in its pipeline of more than 180 projects, and it confirmed its 2026 outlook and its $80 billion revenue target for 2030. Restructuring could mean job cuts, though none have been announced.
Sources